FDA Inspection 1202740 — Avesta Pharma Private Limited

Avesta Pharma Private Limited — FEI 3010165135

The FDA completed an inspection of Avesta Pharma Private Limited on March 24, 2023 in Palghar. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
March 24, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Palghar (India)